Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Becton Dickinson (BDX)

NYSE: BDX · Medical Instruments · Franklin Lakes, NJ

Our rating: Positive

Positive reaffirmed at $177.07, moderate conviction, August 6, 2026.

Breaks if: The Positive call breaks if reported free cash flow falls below $3.5B on a trailing twelve-month basis at any point in the next four quarters — that would indicate the amortization-heavy income statement is concealing genuine cash-generation erosion rather than non-cash accounting drag. Separately, two consecutive quarters of revenue growth below 3% would dismantle the top-line momentum pillar and move us toward Neutral; both conditions occurring together would move us toward Cautious.

Key figures

Market value$58.0B
Revenue, last 12 months$23.3B
Net income, last 12 months$941M
Free cash flow, last 12 monthsn/a
Price to earnings61.6×
Free cash flow yieldn/a
Dividend yield1.9%
Operating margin10.7%
Return on equity3.8%
Beta to the S&P 5000.39
Volatility, annualized26.7%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
June 30, 2026$5.0B5.4%$1.37n/a
March 31, 2026$4.7B5.2%$-1.11n/a
December 31, 2025$5.3B1.6%$1.34$549M
September 30, 2025$8.3B52.7%$1.72n/a
June 30, 2025$4.7B−5.3%$2.00n/a
March 31, 2025$4.5B−11.2%$1.07n/a
December 31, 2024$5.2B9.8%$1.04$588M
September 30, 2024$5.4B6.9%$1.37n/a

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

7 ledger entries and 46 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.